Swedish Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Swedish pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Swedish Pharma Today - Breaking & Trending Today
Apellis has successfully guided its C3 complement inhibitor Pegcetacoplan to approval in paroxysmal nocturnal hemoglobinuria. Click here to read my analysis. ....
AstraZeneca racks up $275 million with vaccine sales The pharma company s revenue for the quarter rose 15 percent year on year to $7.3 billion, beating analysts forecasts. PUBLISHED BY AstraZeneca’s first-quarter earnings doubled, with its Covid-19 vaccine generating $275 million in revenue. The pharma company’s revenue for the quarter rose 15 percent year on year to $7.3 billion, beating analysts’ forecasts. The quarterly revenue earnings surpassed analysts’ expectations of $6.94 billion, while core earnings of $1.63 cents per share were also ahead of a consensus of $1.48 per share. The Swedish Pharma company has developed the vaccine in collaboration with Oxford University and has said it will not make a profit from the shot during the pandemic. With the quarter results, the company declared the financial details of the vaccine. It also revealed that it was on track to deliver 200 million vaccines per month and maintained its guidance for 2021. Th ....
Share Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily s Project Baseline platform. Called the Mirai study, it will be measuring a digital therapeutics intervention s effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy. Christoph Koenen, EVP and chief medical officer of Ostuka Pharmaceutical Companies U.S., told MobiHealthNews that the pivotal, randomized, controlled trial will enroll as many as 540 patients across the country over 10 weeks of active participation. The study will be measuring safety and participants change from baseline on the Montgomery-Åsberg Depression Rating Scale, a standardized measure of depressive symptoms. ....